TLX-250 is under clinical development by Telix Pharmaceuticals and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Metastatic Renal Cell Carcinoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TLX-250’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TLX-250 is under development for the treatment of solid tumor, metastatic renal cell carcinoma and metastatic colorectal cancer. 177Lu-DOTA-cG250 is administered as infusion through intravesical and intravenous route. Lutetium-177 labeled cG250 is a radioimmunoconjugate consisting of the chimeric monoclonal antibody Girentuximab linked to the low energy beta-emitting radioisotope Lutetium 177, via the bi-functional macro-cyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) with anti-neoplastic activity.
Telix Pharmaceuticals overview
Telix Pharmaceuticals (Telix) is a commercial-stage biopharmaceutical company that develops and commercializes radiopharmaceuticals to detect and treat cancer. It offers Illuccix, an imaging agent targeting men with prostate cancer. The company is investigating TLX250-CDx (companion diagnostic) an imaging agent to diagnose renal cancer using positron emission tomography (PET) and TLX250, a radiopharmaceutical therapy against renal cancer. Telix is also evaluating TLX591, an antibody-based therapeutic radiopharmaceutical to treat prostate cancer, TLX101 drug for the treatment of glioblastoma (GBM) and TLX66-CDx and TLX66 programs for bone marrow conditioning. It utilizes molecularly-targeted radiation (MTR) technology, where a radionuclide is attached to a targeting small molecule or antibody that binds to tumor cells and destroys them. The company operates in America, Europe, the Middle East, Africa, and Asia Pacific Regions. Telix is headquartered in Melbourne, Victoria, Australia.
For a complete picture of TLX-250’s drug-specific PTSR and LoA scores, buy the report here.